ABBV-CLS-484 is an investigational small molecule designed for the treatment of autoimmune diseases. It functions as a selective degrader of key signaling proteins involved in inflammatory pathways, particularly targeting components within the immune system that drive chronic inflammation. This compound is being explored for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where modulation of immune response is critical. By promoting the degradation of specific pathogenic proteins, ABBV-CLS-484 aims to offer a more targeted therapeutic effect with potentially fewer systemic side effects compared to broad immunosuppressants. It is currently in early-stage clinical development, with ongoing studies evaluating its safety, pharmacokinetics, and preliminary efficacy in humans.